Ireland-based cinema operator Omniplex has taken a 5.35% stake in Everyman Media Group (LON: EMAN). The share price rebounded 13.7% to 29p.
ImmuPharma (LON: IMM) has received a first Combined Search and Examination Report for the UK patent for autoimmune disease programme P140. A supporting study has been completed. The company recently raised £6.5m at 6p/share. ImmuPharma says that there is significant interest from potential licence partners for P140. The share price improved 10.3% to 5.015p.
Rockrose Energy has bought more shares in bid target Deltic Energy (LON: DELT). It acquired 529,000 shares at 3.4822p each, taking the shareholding in the oil and gas company to 3.19%. The recommended offer is 7.46p/share. The share price rose 7.14% to 3.75p.
Hargreaves Services (LON: HSP) has launched a tender offer at 850p/share. Originally, the indicative price was 750p and the amount being spent has been raised from £15m to £20m. Further renewable assets have been sold since the original announcement. The share price increased 7.14% to 785p.
FALLERS
Switch Metals (LON: SWT) has announced the washing programme has been completed for the Issia tantalum and lithium in the Côte d’Ivoire. Laboratory assays and modelling is ongoing so that the maiden mineral resource estimate can be published. This had been expected in the first quarter of 2026. The share price dived 24.1% to 11p.
Interim figures for Parkmead Group (LON: PMG) had £12.9m in cash at the end of 2025 and since then the cash position has grown to £16.1m. This will provide funding for oil and gas and renewable asset investment. Up to £120m more can become payable for the past sale of UK North Sea assets depending on the approval of field developments. The share price slipped 8.33% to 22p.
Computer vision technology Seeing Machines (LON: SEE) says that it expects to be EBITDA positive in the third and fourth quarters of the financial year to June 2026. Interim revenues dipped from $25.3m to $23.4m, due to planned reductions in non-core operations. Automotive royalties and aftermarket revenues both increased and gross margin improved to 58%. There will be a refinancing by June. The share price declined 4.84% to 2.95p.
Coiled Therapeutics (LON: COIL), which was formerly Roquefort Therapeutics, has moved from the Main Market to AIM acquiring the global rights to a potential cancer treatment known as AO-252. This cost £31.9m in shares. AO-252 is “a brain-penetrant small molecule targeting Transforming Acidic Coiled-Coil Containing protein 3 (TACC3) protein-protein interactions”. Preclinical trials have indicated the effectiveness in tumour regression in some cancers. A placing is raised £8.5m at 10p/share. valuing the company at £42.6m. The share price initially fell 5% but recovered to 10p.